Skip to main content

Multiple Myeloma

Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Newly Diagnosed with measurable disease
  • No Prior Therapy

Dana Farber DFCI 14-508

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination for patients with Newly Diagnosed Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Must have had transplant due to high-risk features / Engraftment of neutrophils ANC greater than 1000 / Engraftment of platelets, PLT greater than 60 / Achievement of at least a PR prior to transplant / Absence of GI symptoms / Cord blood or haplo transplant not allowed

MM 42 SCRI Millennium

Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD)

Newly Diagnosed

Criteria to qualify for this study: Drug used in study:
  • Must have at least 10% plasma cells in the marrow M-protein must be present in the serum and/or urine
  • Must have at least 1 myeloma-related organ dysfunction per CRAB criteria
  • Cannot have amyloid
  • PLT must be at least 50 unless marrow contains >50% plasma cells - then PLT must be at least 30
  • ANC must be at least 1000

Dana Farber DFCI 10-106

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age


Criteria to qualify for this study: Drug used in study:
  • Serum monoclonal protein ≥ 3 gm/dL and > 10% plasma cells in the bone marrow with a free light chain ratio outside the range of 0.125 to 8 OR Ratio or abnormal to normal bone marrow plasma cells ≥ 95% or at least one immunoglobulin level lower than the normal range
  • No evidence of CRAB criteria
  • Prior therapy for active Myeloma excluded

Dana Farber DFCI 14-338 CA-204-119

Phase II Trial of Combination of Elotuxzumab and Lenalidomide ± Dexamethasone in High-Risk Smoldering Multiple Myeloma


Criteria to qualify for this study: Drug used in study:
  • Must have relapsed or relapsed-and-refractory MM
  • Must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of proteasome inhibitor (same or separate regimens)
  • Must have measurable disease (serum M protein > 0.5g/dL or urine M protein > 200mg/24 hrs).

MM 65 ACE-MM-200

A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Subjects must have received prior 1 or 2 lines of treatment that should have included at least 2 consecutive cycles of lenalidomide (full therapeutic dose)
  • Lenalidomide regimen to which subject has relapsed or been refractory to is not required to be the most recent regimen received
  • Measurable dz with Serum M protein > 0.5, Urine M proetin > 200, Involved SFLC > 10
  • Excluded if prior pomalidomide or elotuzumab treatment / see protocol for washout periods

MM 66 CA204142 Bristol-Myers Squibb

A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low-Dose Dexamethasone (Epd) in Patients with Multiple Myeloma Relpased or Refractory to Prior Treatment with Lenalidomide

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory
  • Serum M protein must be at least 1.0 g/dL
  • Urine M proteint must be at least 200 mg/24hr
  • Patients requiring anticoagulation with warfarin are excluded
  • ANC must be at least 1000
  • PLT must be at least 75
  • HGB must be at least 8

MM 51 SCRI PCYC-1119-CA

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibruitnib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma